Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.
Administration, Intravenous
Administration, Rectal
Animals
CD8-Positive T-Lymphocytes
/ immunology
Disease Progression
Female
HIV Infections
/ immunology
HIV-1
Humans
Macaca mulatta
Male
Simian Acquired Immunodeficiency Syndrome
/ classification
Simian Immunodeficiency Virus
/ immunology
Time Factors
Translational Research, Biomedical
Viral Load
Viremia
/ immunology
AIDS/HIV
Adaptive immunity
Cellular immune response
Immunology
T cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
21
05
2021
accepted:
22
07
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
16
11
2021
Statut:
ppublish
Résumé
Primary HIV-1 infection can be classified into six Fiebig stages based on virological and serological laboratory testing, whereas simian-HIV (SHIV) infection in nonhuman primates (NHPs) is defined in time post-infection, making it difficult to extrapolate NHP experiments to the clinics. We identified and extensively characterized the Fiebig-equivalent stages in NHPs challenged intrarectally or intravenously with SHIVAD8-EO. During the first month post-challenge, intrarectally challenged monkeys were up to 1 week delayed in progression through stages. However, regardless of the challenge route, stages I-II predominated before, and stages V-VI predominated after, peak viremia. Decrease in lymph node (LN) CD4+ T cell frequency and rise in CD8+ T cells occurred at stage V. LN virus-specific CD8+ T cell responses, dominated by degranulation and TNF, were first detected at stage V and increased at stage VI. A similar late elevation in follicular CXCR5+ CD8+ T cells occurred, consistent with higher plasma CXCL13 levels at these stages. LN SHIVAD8-EO RNA+ cells were present at stage II, but appeared to decline at stage VI when virions accumulated in follicles. Fiebig-equivalent staging of SHIVAD8-EO infection revealed concordance of immunological events between intrarectal and intravenous infection despite different infection progressions, and can inform comparisons of NHP studies with clinical data.
Identifiants
pubmed: 34623326
pii: 151632
doi: 10.1172/JCI151632
pmc: PMC8409578
doi:
pii:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Références
J Int AIDS Soc. 2020 Jan;23(1):e25444
pubmed: 31953919
Nat Commun. 2020 Jan 7;11(1):70
pubmed: 31911610
J Virus Erad. 2016;2:43-48
pubmed: 26889497
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S187-99
pubmed: 23764635
Nature. 2018 Nov;563(7731):360-364
pubmed: 30283138
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
J Virol. 1999 Feb;73(2):1573-9
pubmed: 9882363
Sci Adv. 2019 May 29;5(5):eaav7116
pubmed: 31149634
Am J Pathol. 1993 Jun;142(6):1750-8
pubmed: 8506945
Am J Pathol. 1988 Dec;133(3):516-24
pubmed: 3059804
Histopathology. 1997 Jan;30(1):31-40
pubmed: 9023555
Nat Med. 2016 Apr;22(4):362-8
pubmed: 26998834
Front Immunol. 2014 Mar 19;5:85
pubmed: 24678309
J Virol. 2005 Jul;79(14):9217-27
pubmed: 15994816
Blood. 2001 May 1;97(9):2695-701
pubmed: 11313260
PLoS Pathog. 2014 Sep 25;10(9):e1004406
pubmed: 25254512
PLoS Pathog. 2016 Jul 27;12(7):e1005777
pubmed: 27463374
PLoS One. 2012;7(3):e33948
pubmed: 22479485
Curr Top Microbiol Immunol. 2018;417:69-109
pubmed: 29026923
J Immunol. 2014 Nov 1;193(9):4527-36
pubmed: 25246494
Sci Transl Med. 2020 Mar 4;12(533):
pubmed: 32132218
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74
pubmed: 23129652
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
Blood. 2012 Nov 15;120(20):4172-81
pubmed: 22990012
JAMA. 1998 Jul 1;280(1):42-8
pubmed: 9660362
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
J Immunol. 2016 Sep 1;197(5):1832-42
pubmed: 27481845
Lancet HIV. 2018 Jan;5(1):e35-e44
pubmed: 28978417
J Clin Invest. 2012 Sep;122(9):3281-94
pubmed: 22922258
J Exp Med. 2013 Jan 14;210(1):143-56
pubmed: 23254284
J Virol. 2016 Oct 28;90(22):10339-10350
pubmed: 27630228
Nature. 2000 Jul 20;406(6793):309-14
pubmed: 10917533
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Nat Med. 2017 Nov;23(11):1277-1286
pubmed: 29035370
J Int AIDS Soc. 2017 Jun 26;20(1):21652
pubmed: 28691436
Immunity. 2007 Aug;27(2):190-202
pubmed: 17723214
J Exp Med. 2000 Dec 4;192(11):1545-52
pubmed: 11104797
Nature. 2013 Nov 14;503(7475):277-80
pubmed: 24172896
J Interferon Cytokine Res. 2005 Nov;25(11):702-6
pubmed: 16318584
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
BMC Infect Dis. 2011 Mar 01;11:56
pubmed: 21362195
J Virol. 2017 Jul 27;91(16):
pubmed: 28539448
J Virol. 2003 Nov;77(22):11896-909
pubmed: 14581526
J Virol. 2009 Apr;83(8):3719-33
pubmed: 19176632
J Exp Med. 2021 Jan 4;218(1):
pubmed: 32966579
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100833
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
Nature. 2009 Apr 23;458(7241):1034-8
pubmed: 19262509
AIDS. 1991 Sep;5(9):1071-9
pubmed: 1930770
J Exp Med. 2014 Sep 22;211(10):2061-74
pubmed: 25155019
AIDS. 2016 Jan;30(2):193-201
pubmed: 26558730
J Virol. 2015 Nov 18;90(3):1321-32
pubmed: 26581981
Curr HIV/AIDS Rep. 2012 Jun;9(2):101-10
pubmed: 22415472
J Clin Invest. 2018 May 1;128(5):2089-2103
pubmed: 29664020
J Clin Invest. 2012 Sep;122(9):3271-80
pubmed: 22922259
J Virol. 2018 May 14;92(11):
pubmed: 29563297
Nat Med. 2015 Feb;21(2):132-9
pubmed: 25599132
J Theor Biol. 2009 Nov 21;261(2):341-60
pubmed: 19660475